Stockwatch: Will Coronavirus Drug Developments Rescue The Sector’s Pricing Reputation?
Mid-Year Drug Price Increases Threaten Biopharma's Coronavirus Reputation Boost
Can the development of coronavirus vaccines and therapeutics reverse the demonization of the pharmaceutical sector brought about by drug price increases?
You may also be interested in...
Stock Watch: AstraZeneca’s Third-Quarter Crescendo
In a third-quarter earnings report that was difficult to fault AstraZeneca left big pharma earnings season on a high note. But raised full-year guidance depends on Evusheld sales and maybe China.
Stock Watch: How To Avoid Blockbuster Loss Of Exclusivity Bringing Your Company Down
What is the difference between companies with franchises that rise and then fall into obscurity, and those that keep on rising even after loss of exclusivity?
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.